<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mechanical assist devices for acute cardiogenic shock - Ni hIci, T - 2020 | Cochrane Library</title> <meta content="Mechanical assist devices for acute cardiogenic shock - Ni hIci, T - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013002.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mechanical assist devices for acute cardiogenic shock - Ni hIci, T - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013002.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013002.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Mechanical assist devices for acute cardiogenic shock" name="citation_title"/> <meta content="Tamara Ni hIci" name="citation_author"/> <meta content="Morriston Hospital" name="citation_author_institution"/> <meta content="tamaranihici@gmail.com" name="citation_author_email"/> <meta content="Henry MP Boardman" name="citation_author"/> <meta content="John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Kamran Baig" name="citation_author"/> <meta content="Guy's and St Thomas' NHS Foundation Trust" name="citation_author_institution"/> <meta content="Jody L Stafford" name="citation_author"/> <meta content="University Hospital of Wales" name="citation_author_institution"/> <meta content="Cristina Cernei" name="citation_author"/> <meta content="Swansea University" name="citation_author_institution"/> <meta content="Owen Bodger" name="citation_author"/> <meta content="Swansea University" name="citation_author_institution"/> <meta content="Stephen Westaby" name="citation_author"/> <meta content="John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD013002.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/06/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013002.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013002.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013002.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Coronary Care Units [statistics &amp; numerical data]; *Heart-Assist Devices [adverse effects]; Length of Stay; Quality of Life; Renal Dialysis [statistics &amp; numerical data]; Shock, Cardiogenic [*mortality, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013002.pub2&amp;doi=10.1002/14651858.CD013002.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013002\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013002\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013002.pub2",title:"Mechanical assist devices for acute cardiogenic shock",firstPublishedDate:"Jun 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013002.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013002.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013002.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013002.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013002.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013002.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013002.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013002.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013002.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013002.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5082 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013002.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/appendices#CD013002-sec-0078"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/table_n/CD013002StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/table_n/CD013002StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mechanical assist devices for acute cardiogenic shock</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Tamara Ni hIci</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0005">Henry MP Boardman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0006">Kamran Baig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0007">Jody L Stafford</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0008">Cristina Cernei</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0009">Owen Bodger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information#CD013002-cr-0010">Stephen Westaby</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information/en#CD013002-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 June 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013002.pub2">https://doi.org/10.1002/14651858.CD013002.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013002-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013002-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013002-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013002-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013002-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013002-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013002-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013002-abs-0001" lang="en"> <section id="CD013002-sec-0001"> <h3 class="title" id="CD013002-sec-0001">Background</h3> <p>Cardiogenic shock (CS) is a state of critical end‐organ hypoperfusion due to a primary cardiac disorder. For people with refractory CS despite maximal vasopressors, inotropic support and intra‐aortic balloon pump, mortality approaches 100%. Mechanical assist devices provide mechanical circulatory support (MCS) which has the ability to maintain vital organ perfusion, to unload the failing ventricle thus reduce intracardiac filling pressures which reduces pulmonary congestion, myocardial wall stress and myocardial oxygen consumption. This has been hypothesised to allow time for myocardial recovery (bridge to recovery) or allow time to come to a decision as to whether the person is a candidate for a longer‐term ventricular assist device (VAD) either as a bridge to heart transplantation or as a destination therapy with a long‐term VAD. </p> </section> <section id="CD013002-sec-0002"> <h3 class="title" id="CD013002-sec-0002">Objectives</h3> <p>To assess whether mechanical assist devices improve survival in people with acute cardiogenic shock. </p> </section> <section id="CD013002-sec-0003"> <h3 class="title" id="CD013002-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and Web of Science Core Collection in November 2019. In addition, we searched three trials registers in August 2019. We scanned reference lists and contacted experts in the field to obtain further information. There were no language restrictions. </p> </section> <section id="CD013002-sec-0004"> <h3 class="title" id="CD013002-sec-0004">Selection criteria</h3> <p>Randomised controlled trials on people with acute CS comparing mechanical assist devices with best current intensive care management, including intra‐aortic balloon pump and inotropic support. </p> </section> <section id="CD013002-sec-0005"> <h3 class="title" id="CD013002-sec-0005">Data collection and analysis</h3> <p>We performed data collection and analysis according to the published protocol.</p> <p>Primary outcomes were survival to discharge, 30 days, 1 year and secondary outcomes included, quality of life, major adverse cardiovascular events (30 days/end of follow‐up), dialysis‐dependent (30 days/end of follow‐up), length of hospital stay and length of intensive care unit stay and major adverse events. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes </p> <p>Summary statistics for the primary endpoints were risk ratios (RR), hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs). </p> </section> <section id="CD013002-sec-0006"> <h3 class="title" id="CD013002-sec-0006">Main results</h3> <p>The search identified five studies from 4534 original citations reviewed. Two studies included acute CS of all causes randomised to treatment using TandemHeart percutaneous VAD and three studies included people with CS secondary to acute myocardial infarction who were randomised to Impella CP or best medical management. Meta‐analysis was performed only to assess the 30‐day survival as there were insufficient data to perform any further meta‐analyses. The results from the five studies with 162 participants showed mechanical assist devices may have little or no effect on 30‐day survival (RR of 1.01 95% CI 0.76 to 1.35) but the evidence is very uncertain. </p> <p>Complications such as sepsis, thromboembolic phenomena, bleeding and major adverse cardiovascular events were not infrequent in both the MAD and control group across the studies, but these could not be pooled due to inconsistencies in adverse event definitions and reporting. </p> <p>We identified four randomised control trials assessing mechanical assist devices in acute CS that are currently ongoing. </p> </section> <section id="CD013002-sec-0007"> <h3 class="title" id="CD013002-sec-0007">Authors' conclusions</h3> <p>There is no evidence from this review of a benefit from MCS in improving survival for people with acute CS. Further use of the technology, risk stratification and optimising the use protocols have been highlighted as potential reasons for lack of benefit and are being addressed in the current ongoing clinical trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013002-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013002-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013002-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013002-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013002-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013002-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013002-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013002-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013002-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013002-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013002-abs-0002" lang="en"> <h3>Mechanical heart pumps to aid a heart that fails suddenly</h3> <p><b>Background</b> </p> <p>Conditions that prevent the heart pumping effectively remain the leading cause of death globally. A heart attack is the most common condition that causes the heart pump to fail (called cardiogenic shock), but other causes exist such as viral infections, heart valve disease and problems with the muscle. When the heart muscle has been damaged so extensively that it can no longer pump effectively function has to be improved or organ damage and death will occur. Even with the best treatments that we currently have, the risk of dying is extremely high. Mechanical assist devices that can help the heart to pump more effectively have been developed so that the heart can recover from the insult. </p> <p>However, the evidence for these treatments is scare and the aim of this review is to assess if these devices do help more people to survive. We assessed randomised control trials (clinical studies where people are randomly put into one of two or more treatment groups) where these devices were used and compare the outcome of these people to those who did not receive a device and received best medical treatment (with medicines to help the heart to pump). </p> <p><b>Results</b> </p> <p>The evidence is current to 25 November 2019.</p> <p>We identified five trials that enrolled 162 people in shock due to their heart failing. These people were randomised to using mechanical assist devices with current best management practice or current best medical management alone (which includes medicines to help the heart to pump more effectively). </p> <p>The quality of the evidence was very low, due to difficulties in accounting for biases (one cannot hide the fact that a person receives a mechanical assist device, difficulty in enrolling participants, gaining consent when a person is very close to dying, and variations in the protocols on the timing of the devices and the types of devices used). </p> <p>From the data, there was little or no effect on survival at 30 days if a device was used alongside current best medical management or current best medical management alone. However, we are uncertain about these findings.  </p> <p>Complications such as sepsis, thromboembolic phenomena, bleeding and major adverse cardiovascular events were not infrequent in both the MAD and control group across the studies, but these could not be pooled due to inconsistencies in adverse event definitions and reporting. </p> <p>Currently there are four ongoing trials. They are assessing if they can improve outcomes by selecting the people who would most likely have a benefit. </p> <p><b>Conclusions</b> </p> <p>In conclusion, this review was unable to assess if mechanical assist devices help people with cardiogenic shock due to their heart failing. We await the results of the ongoing trials, which we anticipate will help clarify whether these devices will help people to survive with a full recovery or not. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013002-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013002-sec-0073"></div> <h3 class="title" id="CD013002-sec-0074">Implications for practice</h3> <section id="CD013002-sec-0074"> <p>We are uncertain about the effects of mechanical circulatory support in improving survival for people with acute cardiogenic shock. </p> <p>Further use of the technology, risk stratification and optimising the use protocols may help to improve the situation. </p> <p>The results of this review should not have implication for practice.</p> </section> <h3 class="title" id="CD013002-sec-0075">Implications for research</h3> <section id="CD013002-sec-0075"> <p>The small number of participants included in this review and the very‐low quality of evidence indicate that further research is highly likely to change the estimated effect. </p> <p>An effort should be made for future trials to define and report complications in a consistent manner as this would allow comparisons across studies, and pooling of the data. This is crucial in this field as sample sizes in these studies tend to be quite small. </p> <p>The devices available for mechanical circulatory support and clinicians experience in selecting patients and when to implant them is fast developing. Most participants included in this review were randomised pre‐2010. Further research will be key in identifying whether there are subgroups of patients who can benefit from this treatment and the magnitude of this benefit. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013002-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013002-sec-0008"></div> <div class="table" id="CD013002-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mechanical assist devices compared to intra‐aortic balloon pump for acute cardiogenic shock at 30‐day follow‐up</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MAD compared to IABP for acute cardiogenic shock 30‐day follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with acute cardiogenic shock<br/><b>Setting:</b> hospital or intensive care unit<br/><b>Intervention:</b> MAD<br/><b>Comparison:</b> IABP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IABP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MAD</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>30‐day survival</b> </p> <p>Follow‐up of 30 days was complete in all 5 studies.</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.01</b><br/>(0.76 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000<br/>(395 to 715) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study described quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies described MACE events in a very heterogeneous manner without any clear definitions in any of the studies (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). CVA occurred in 1 participant who had a MAD and 1 participant who had IABP only (both in <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> and both CVA were ischaemic). <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> was the only study to describe if any cases had myocardial reinfarction reporting that this occurred in 1 participant who had MAD and 2 participants who had IABP only. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> described that 1 participant had a major vascular complication, with a retroperitoneal bleed after percutaneous MAD insertion. <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> described that 7 participants developed limb ischaemia following insertion of a 17‐French arterial cannula. Limb ischaemia could be resolved by surgical approach in 3 participants and by percutaneous approach in 4 participants. <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a> described limb ischaemia requiring surgery after device explantation in 1 participant assigned to Impella MAD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dialysis‐dependent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8/24 33%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7/24 29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> reported 8/24 (33%) participants in MAD group and 7/24 (29%) in IABP group required dialysis with duration of treatment (median) 17 (25th to 75th percentile 5–29) days in MAD group and (median) 7 (25th to 75th percentile 2–9) days in IABP group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay (hospital)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study described length of stay <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> MAD median 16 days (25th to 75th percentile 2–26) and IABP median 10 days (25th to 75th percentile 6–24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay (ICU)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study described length of ICU stay <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> MAD median 7 days (25th to 75th percentile 3–16) IABP median 7 days (25th to 75th percentile 4–10) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b> </p> <p>Mean follow‐up time 30 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were heterogeneous. <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a> had 1 device failure TandemHeart blood clot in the cannula, also described 21.5% of participants in MAD group developed sepsis vs 35.7% in IABP group. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> stated that 33% in MAD group had significant bleeding vs 8% in IABP. <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> stated that 61% in MAD group had evidence of DIC vs 15% in IABP group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CVA:</b> cardiovascular accident; <b>DIC:</b> disseminated intravascular coagulation; <b>IABP:</b> intra‐aortic balloon pump; <b>ICU:</b> intensive care unit; <b>MACE:</b> major adverse cardiovascular events; <b>MAD:</b> mechanical assist device; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: the majority of studies were at high or unclear risk of bias for at least one key domain.<br/><sup>b</sup>Downgraded two levels for imprecision: 95% CI is wide and includes the possibility of both harm and benefit, and the sample size is very low small. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013002-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013002-sec-0009"></div> <section id="CD013002-sec-0010"> <h3 class="title" id="CD013002-sec-0010">Description of the condition</h3> <p>See <a href="./appendices#CD013002-sec-0079">Appendix 1</a> for a glossary of terms. </p> <p>Acute cardiogenic shock (ACS) is a state of inadequate organ perfusion secondary to acute heart failure (<a href="./references#CD013002-bbs2-0070" title="ShekarK , GregorySD , FraserJF . Mechanical circulatory support in the new era: an overview. Critical Care (London, England)2016;20(1):66.">Shekar 2016</a>). This is characterised by persistent hypotension (systolic blood pressure less than 80 mmHg to 90 mmHg or mean arterial blood pressure 30 mmHg lower than baseline, for more than 30 minutes) with reduction in Cardiac Index to less than 1.8 L/minute/m² without haemodynamic support or less than 2.0 L/minute/m² to 2.2 L/minute/m² with support and elevated filling pressures (left ventricular end‐diastolic pressure (LVEDP) greater than 18 mmHg or right ventricular end‐diastolic pressure (RVEDP) greater than 10 mmHg to 15 mmHg), a pulmonary capillary wedge pressure greater than 15 mmHg in the setting of adequate or elevated filling pressure, and clinical features of hypoperfusion (cool extremities, decreased urine output, or altered sensorium) (<a href="./references#CD013002-bbs2-0062" title="MandawatA , RaoSV . Percutaneous mechanical circulatory support devices in cardiogenic shock. Circulation. Cardiovascular Interventions2017;10:e004337.">Mandawat 2017</a>; <a href="./references#CD013002-bbs2-0067" title="ReynoldsH , HochmanS . Cardiogenic shock: current concepts and improving outcomes. Circulation2008;117:686-97.">Reynolds 2008</a>; <a href="./references#CD013002-bbs2-0068" title="RihalCS , NaiduSS , GivertzMM , SzetoWY , BurkeJA , KapurNK , et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. Journal of the American College of Cardiology2015;65(19):e7-e26.">Rihal 2015</a>). </p> <p>Despite advances in the management of cardiogenic shock, it remains the leading cause of death in hospitalised people, regardless of aetiologies (<a href="./references#CD013002-bbs2-0039" title="ChungSY , SheuJJ , LinYJ , SunCK , ChangLT , ChenYL , et al. Outcomes of patients with profound cardiogenic shock after cardiopulmonary resuscitation and prompt extracorporeal membrane oxygenation support. A single-centre observational study. Circulation2012;6:1385-92.">Chung 2012</a>; <a href="./references#CD013002-bbs2-0077" title="World Health Organization. Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000–2016. www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html (accessed prior to 7 May 2020).">WHO 2018</a>). The incidence of ACS has increased two‐fold from approximately 55,123 in 2004 to 126,555 in 2014, according to the largest publicly available data in the USA (<a href="./references#CD013002-bbs2-0062" title="MandawatA , RaoSV . Percutaneous mechanical circulatory support devices in cardiogenic shock. Circulation. Cardiovascular Interventions2017;10:e004337.">Mandawat 2017</a>). Furthermore, the prognosis of ACS remains poor, with only 48% of people surviving from diagnosis to hospital discharge, despite higher rates of revascularisation and use of intra‐aortic balloon pumps (IABP) (<a href="./references#CD013002-bbs2-0062" title="MandawatA , RaoSV . Percutaneous mechanical circulatory support devices in cardiogenic shock. Circulation. Cardiovascular Interventions2017;10:e004337.">Mandawat 2017</a>). </p> <p>Myocardial infarction with left ventricular failure is the most common cause of cardiogenic shock, and cardiogenic shock occurs in approximately 5% to 8% of people hospitalised with ST elevation myocardial infarction (STEMI) and 2.5% of non‐STEMI cases (<a href="./references#CD013002-bbs2-0035" title="BabaevA , FrederickPD , PastaDJ , EveryN , SichrovskyT , HochmanJS . Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA2005;294:448-54.">Babaev 2005</a>; <a href="./references#CD013002-bbs2-0045" title="FoxKA , Anderson FA Jr, DabbousOH , StegPG , Lopez-SendonJ , Vande WerfF , et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart2007;93:177-82.">Fox 2007</a>; <a href="./references#CD013002-bbs2-0049" title="HasdaiD , HarringtonRA , HochmanJS , CaliffRM , BattlerA , BoxJW , et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. Journal of American College of Cardiology2000;36:685-92.">Hasdai 2000</a>). When cardiogenic shock complicates an acute myocardial infarction, the reported mortality rate is between 85% and 90% (<a href="./references#CD013002-bbs2-0047" title="GoldbergRJ , GoreJR , ThompsonCA , GurwitzJH . Recent magnitude of and temporal trends (1994–1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second National Registry of Myocardial Infarction. American Heart Journal2001;141:65-72.">Goldberg 2001</a>). Any cause of acute and severe left ventricular or right ventricular dysfunction can lead to cardiogenic shock. Acute myopericarditis, Takotsubo cardiomyopathy, and peripartum cardiomyopathy can all lead to reversible ventricular dysfunction which have good long‐term prognosis, but only if the person can be supported through the acute phase of cardiac failure and cardiogenic shock (<a href="./references#CD013002-bbs2-0043" title="EmmertMY , PrêtreR , RuschitzkaF , KrhenmannF , FalkV , WilhelmMJ . Peripartum cardiomyopathy with cardiogenic shock: recovery after prolactin inhibition and mechanical support. Annals of Thoracic Surgery2011;91(1):274-6.">Emmert 2011</a>; <a href="./references#CD013002-bbs2-0056" title="HowellE , PaivanasN , SternJ , VidulaH . Treatment of acute necrotizing eosinophilic myocarditis with immunosuppression and mechanical circulatory support. Circulation. Heart Failure2016;9(12):e003665.">Howell 2016</a>; <a href="./references#CD013002-bbs2-0058" title="KatoS , MorimotoS , HiramitsuS , NomuraM , ItoT , HishidaH . Use of percutaneous cardiopulmonary support of patients with fulminant myocarditis and cardiogenic shock for improving prognosis. American Journal of Cardiology1999;83(4):623-5.">Kato 1999</a>; <a href="./references#CD013002-bbs2-0064" title="OmerovicE . Takotsubo syndrome – scientific basis for current treatment strategies. Heart Failure Clinics2016;12(4):577-86.">Omerovic 2016</a>; <a href="./references#CD013002-bbs2-0078" title="Zalewska-AdamiecM , Bachorzewska-GajewskaH , Tomaszuk-KazberukA , NowakK , DrozdowskiP , BychowskiJ , et al. Takotsubo cardiomyopathy: serious early complications and two-year mortality – a 101 case study. Netherlands Heart Journal2016;24(9):511-9.">Zalewska‐Adamiec 2016</a>). </p> </section> <section id="CD013002-sec-0011"> <h3 class="title" id="CD013002-sec-0011">Description of the intervention</h3> <p>For people with refractory cardiogenic shock despite maximal vasopressors, inotropic support and IABP, mortality approaches 100% with few people surviving (<a href="./references#CD013002-bbs2-0054" title="HochmanJS , SleeperLA , WhiteHD , DzavikV , WongSC , MenonV , et al. One year survival following early revascularization for cardiogenic shock. JAMA2001;285:190-2.">Hochman 2001</a>). Survival in these cases may be possible by providing complete circulatory support with a mechanical assist device (MAD) (<a href="./references#CD013002-bbs2-0050" title="HendryPJ , MastersRG , MussivandTV , SmithS , DaviesRA , FinlayS , et al. Circulatory support for cardiogenic shock due to acute myocardial infarction: a Canadian experience. Canadian Journal of Cardiology1999;15(10):1090-4.">Hendry 1999</a>; <a href="./references#CD013002-bbs2-0052" title="HillJD , FarrarDJ , HershonJJ , ComptonPG , Avery GJ 2nd, LevinBS , et al. Use of a prosthetic ventricle as a bridge to cardiac transplantation for postinfarction cardiogenic shock. New England Journal of Medicine1986;314:626-8.">Hill 1986</a>; <a href="./references#CD013002-bbs2-0055" title="HolmanWL , RoyeGD , BourgeRC , McGiffinDC , IyerSS , KirklinJK . Circulatory support for myocardial infarction with ventricular arrhythmias. Annals of Thoracic Surgery1995;59(5):1230-1.">Holman 1995</a>). </p> <p>MADs provide mechanical circulatory support (MCS) that has the ability to maintain vital organ perfusion, to unload the failing ventricle thus reducing intracardiac filling pressures which reduces pulmonary congestion, myocardial wall stress and myocardial oxygen consumption. MADs also have the ability to augment coronary perfusion by supporting the circulation during procedures which aim to treat the underlying cause of cardiogenic shock, such as revascularisation or ablation of ventricular arrhythmia (<a href="./references#CD013002-bbs2-0046" title="FriedelN , ViazisP , SchiesslerA , WarneckeH , HennigE , TrittinA , et al. Recovery of end-organ failure during mechanical circulatory support. European Journal of Cardiothoracic Surgery1992;6(10):519-22.">Friedel 1992</a>; <a href="./references#CD013002-bbs2-0068" title="RihalCS , NaiduSS , GivertzMM , SzetoWY , BurkeJA , KapurNK , et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. Journal of the American College of Cardiology2015;65(19):e7-e26.">Rihal 2015</a>). This can allow time for myocardial recovery (bridge to recovery) or allow time to come to a decision as to whether the person is a candidate for a longer‐term ventricular assist device (VAD) either as a bridge to heart transplantation or as a destination therapy with a long‐term VAD (<a href="./references#CD013002-bbs2-0040" title="CopelandJG , SmithRG , ArabiaFA , NolanPE , SethiGK , TsauPH , et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. New England Journal of Medicine2004;351(9):859-67.">Copeland 2004</a>). </p> </section> <section id="CD013002-sec-0012"> <h3 class="title" id="CD013002-sec-0012">How the intervention might work</h3> <p>Current devices can be divided into categories: short‐term versus long‐term devices; paracorporeal versus intracorporeal; pulsatile versus continuous flow devices; full versus partial support devices; percutaneous versus surgical; and assist devices versus complete heart replacement (total artificial heart) (<a href="./references#CD013002-bbs2-0069" title="SellkeFW , delNidoPH , SwansonSJ . Sabiston &amp; Spencer Surgery of the Chest. 8th edition. Vol. II. Philadelphia (PA): Saunders Elsevier, 2010.">Sellke 2010</a>). </p> <p>In people presenting with critical circulatory instability, the chosen mechanical assistance should be rapidly available and easily implantable. Standard cardiopulmonary bypass is designed to ensure minutes to hours of support for people undergoing cardiac surgery. Extracorporeal membrane oxygenation (ECMO) provides continuous flow support to people with respiratory, cardiac or combined cardiopulmonary failure for days to weeks. Deoxygenated blood is drained from the venous system, the pulmonary system is bypassed by placing an oxygenator in parallel with the native lungs and pumped in a continuous manner using a centrifugal or roller pump back to the arterial circulation (<a href="./references#CD013002-bbs2-0036" title="BartlettRH , GattinoniL . Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiologica2010;76:534-40.">Bartlett 2010</a>). Cannulation can be obtained centrally (blood being drained directly from the right atrium and returned to the proximal ascending aorta) or peripherally (blood draining from the proximal femoral or jugular vein and returned to the carotid axillary or femoral artery), typically using the Seldinger technique, via an open or percutaneous approach (<a href="./references#CD013002-bbs2-0038" title="ChamogeorgakisT , LimaB , ShaffiiAE , NagpalD , PokersnikJA , NaviaJL , et al. Outcomes of axillary artery side graft cannulation for extracorporeal membrane oxygenation. Journal of Thoracic and Cardiovascular Surgery2013;145:1088-92.">Chamogeorgakis 2013</a>). </p> <p>Venoarterial ECMO is available for cardiac or cardiopulmonary failure as a bridge to recovery, a bridge to definitive VAD or bridge to heart transplantation (<a href="./references#CD013002-bbs2-0074" title="SquiersJJ , LimaB , DiMaioJM . Contemporary extracorporeal membrane oxygenation therapy in adults: fundamental principles and systematic review of the evidence. Journal of Thoracic and Cardiovascular Surgery2016;152(1):20-32.">Squiers 2016</a>). </p> <p>Similarly, short‐term VADs can be rapidly implantable and provide extracorporeal or paracorporeal pulsatile or continuous flow. VADs support the function of the left ventricle (left ventricular assist device (LVAD)), right ventricle (right ventricular assist device (RVAD)) or both ventricles (biventricular assist device (BiVAD)) depending on what is required for that particular patient. They do not include an oxygenator, thus providing isolated cardiac support. These devices are more expensive but allow the people longer duration of circulatory support and greater opportunity to mobilise (<a href="./references#CD013002-bbs2-0068" title="RihalCS , NaiduSS , GivertzMM , SzetoWY , BurkeJA , KapurNK , et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. Journal of the American College of Cardiology2015;65(19):e7-e26.">Rihal 2015</a>). </p> </section> <section id="CD013002-sec-0013"> <h3 class="title" id="CD013002-sec-0013">Why it is important to do this review</h3> <p>The leading cause of death internationally is cardiovascular disease, and cardiogenic shock is the penultimate point in which there is an opportunity to intervene (<a href="./references#CD013002-bbs2-0061" title="LüTF . Prevention: some important steps forward, but many unmet needs in a world with cardiovascular disease as the leading cause of death. European Heart Journal2016;37(42):3179-81.">Lü 2016</a>). </p> <p>Cardiac surgeons are faced with increasingly complex cases with significant comorbidities, and with quality indexes, such as failure to rescue those who develop complications (e.g. postcardiotomy cardiogenic shock) being increasingly assessed. In order to operate on such complex cases, having the knowledge of the best current evidence will provide hospital trusts with the essential information in providing the necessary equipment and in training staff in the use of mechanical support devices. </p> <p>The National Institute for Health and Care Excellence (NICE) guidelines: <i>Acute heart failure: diagnosis and management</i>, state that "at an early stage, the specialist should have a discussion with a centre providing MCS about people with potentially reversible severe acute heart failure or people who are potential candidates for heart transplantation" (<a href="./references#CD013002-bbs2-0063" title="National Institute for Health and Care Excellence. Acute heart failure: diagnosis and management. nice.org.uk/guidance/cg187 (accessed prior to 7 May 2020).">NICE 2014</a>). </p> <p>The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure include MCS as a treatment option for people who cannot be stabilised on medical treatment alone. In addition to the uses described above, MCS, particularly ECMO, can be used as a 'bridge to decision' in people with cardiogenic shock to achieve haemodynamic stability, to allow consideration of long‐term MCS and heart transplant to be evaluated (<a href="./references#CD013002-bbs2-0065" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>The American Heart Association (AHA) and International Society for Heart and Lung Transplantations guidelines recommend patients with persistent cardiogenic shock with or without end‐organ hypoperfusion, should be evaluated for MCS candidacy by a multidisciplinary team with expertise in the selection, implantation, and management of MADs (<a href="./references#CD013002-bbs2-0032" title="PeuraJL , Colvin-AdamsM , FrancisGS , GradyKL , HoffmanTM , JessupM , et al, on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation2012;126:2648-67.">AHA 2012</a>; <a href="./references#CD013002-bbs2-0057" title="FeldmanD , PamboukianSV , TeutebergJJ , BirksE , LietzK , MooreSA , et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. Journal of Heart and Lung Transplantation2013;32:157-87.">ISHLT 2013</a>). The most recent AHA scientific statement on the contemporary management of cardiogenic shock state, "We suggest that temporary MCS devices can be inserted in patients who are not expected to recover as early as possible in the course of CS [cardiogenic shock] as a bridge to recovery, bridge to a bridge, BTT, or bridge to decision strategy in appropriately selected patients with CS" (<a href="./references#CD013002-bbs2-0033" title="vanDiepenS , KatzJN , AlbertNM , HenryTD , JacobsAK , KapurNK , et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation2017;136(16):e232-68.">AHA 2017</a>). </p> <p>Many cardiology/cardiothoracic centres do not have timely access to temporary mechanical support devices. This review aims to assess the effectiveness of this treatment which would be valuable in guiding patient management and service planning. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013002-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013002-sec-0014"></div> <p>To assess whether mechanical assist devices improve survival in people with acute cardiogenic shock. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013002-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013002-sec-0015"></div> <section id="CD013002-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013002-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing MADs with best current intensive care management, including IABP and inotropic support. We included studies reported as full‐text, those published as abstract only and unpublished data. We did not include cross‐over trials as we were looking at survival data in the setting of people with an exceedingly high mortality risk. </p> </section> <section id="CD013002-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included all participants, irrespective of age (adults and children), with a diagnosis of ACS secondary to any cause. ACS was defined as "a state of organ hypoperfusion secondary to acute cardiac failure" (<a href="./references#CD013002-bbs2-0070" title="ShekarK , GregorySD , FraserJF . Mechanical circulatory support in the new era: an overview. Critical Care (London, England)2016;20(1):66.">Shekar 2016</a>). This is characterised by persistent hypotension (systolic blood pressure less than 80 mmHg to 90 mmHg or mean arterial blood pressure 30 mmHg lower than baseline, for more than 30 minutes) with reduction in Cardiac Index to less than 1.8 L/minute/m² without haemodynamic support or less than 2.2 L/minute/m² with support, and a pulmonary capillary wedge pressure greater than 15 mmHg in the setting of adequate or elevated filling pressure (<a href="./references#CD013002-bbs2-0067" title="ReynoldsH , HochmanS . Cardiogenic shock: current concepts and improving outcomes. Circulation2008;117:686-97.">Reynolds 2008</a>; <a href="./references#CD013002-bbs2-0068" title="RihalCS , NaiduSS , GivertzMM , SzetoWY , BurkeJA , KapurNK , et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. Journal of the American College of Cardiology2015;65(19):e7-e26.">Rihal 2015</a>). </p> <p>We included studies with a subset of eligible participants in the review. When more than one of the included trials was found to have less than 75% of people with the diagnosis of interest, we accepted that this reduces the validity of the results. </p> </section> <section id="CD013002-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention group was any participant treated with a MAD, including ECMO, LVAD, RVAD or BiVAD, compared to the control group which was treated with best current intensive care management, including inotropic support and IABP. </p> </section> <section id="CD013002-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The reporting of outcomes was not a criteria for inclusion in the review.</p> <section id="CD013002-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013002-list-0001"> <li> <p>Survival (measured to: discharge; 30 days; 1 year; end of follow‐up).</p> </li> <li> <p>Survival (measured to: transplant; unsupported cardiac function; end of follow‐up).</p> </li> </ol> </p> </section> <section id="CD013002-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013002-list-0002"> <li> <p>Quality of life (using a validated quality of life scale or questionnaire, measured to: discharge; 30 days; 6 months; 1 year; end of follow‐up). </p> </li> <li> <p>Major adverse cardiovascular events (measured to: discharge; 30 days; 6 months; 1 year; end of follow‐up): </p> <ol id="CD013002-list-0003"> <li> <p>cerebrovascular accidents (persistent central neurological deficit for greater than 72 hours); </p> </li> <li> <p>myocardial infarction;</p> </li> <li> <p>acute limb ischaemia.</p> </li> </ol> </li> <li> <p>Dialysis‐dependent (measured to: discharge; 30 days; 1 year; end of follow‐up).</p> </li> <li> <p>Length of hospital stay and length of intensive care unit stay.</p> </li> <li> <p>Major adverse events, for example, deep sternal wound infection, prolonged ventilation greater than 72 hours (measured to: discharge; 30 days; 6 months; 1 year; end of follow‐up). </p> </li> </ol> </p> </section> </section> </section> <section id="CD013002-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013002-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases on 25 November 2019: </p> <p> <ol id="CD013002-list-0004"> <li> <p>CENTRAL, Issue 11 (the Cochrane Library);</p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 22 November 2019); </p> </li> <li> <p>Embase (Ovid, 1980 to 2019 week 47);</p> </li> <li> <p>Web of Science Core Collection (Clarivate Analytics, 1900 to 25 November 2019).</p> </li> </ol> </p> <p>We adapted the preliminary search strategy for MEDLINE (Ovid) for use in the other databases (<a href="./appendices#CD013002-sec-0080">Appendix 2</a>). We applied the Cochrane sensitivity‐maximising RCT filter to MEDLINE (Ovid) and adaptations of it to the other databases, except CENTRAL (<a href="./references#CD013002-bbs2-0059" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), the UK Clinical Research Network Portfolio Database (<a href="http://public.ukcrn.org.uk" target="_blank">public.ukcrn.org.uk</a>), and Centerwatch (<a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a>) on 4 August 2019. </p> <p>We searched all databases from their inception and we imposed no restriction on language of publication. </p> <p>We searched relevant manufacturers' websites for trial information on 4 August 2019. Manufacturers of MADs that we have identified in previous searches were: Abbott (<a href="http://www.thoratec.com" target="_blank">www.thoratec.com</a>; <a href="http://www.sjmglobal.com" target="_blank">www.sjmglobal.com</a>), Getinge AB (<a href="http://www.maquet.com" target="_blank">www.maquet.com</a>), Medtronic (<a href="http://www.medtronic.com" target="_blank">www.medtronic.com</a>), LivaNova (<a href="https://www.livanova.com/en-US/" target="_blank">www.livanova.com</a>), Hemovent (<a href="http://www.hemoventgmbh.com" target="_blank">www.hemoventgmbh.com</a>), ABIOMED (<a href="http://www.abiomed.com" target="_blank">www.abiomed.com</a>), <a href="http://www.reliantheart.com" target="_blank">www.reliantheart.com</a>, Novacor (<a href="http://www.novacor.co.uk" target="_blank">www.novacor.co.uk</a>), MyLVAD (<a href="http://www.mylvad.com" target="_blank">www.mylvad.com</a>), Jarvik Heart (<a href="http://www.jarvikheart.com" target="_blank">www.jarvikheart.com</a>, <a href="http://www.terumoheart.net" target="_blank">www.terumoheart.net</a>, <a href="http://www.sunshineheart.com" target="_blank">www.sunshineheart.com</a>). </p> </section> <section id="CD013002-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of included studies and review articles for additional references. We contacted trial authors for missing data and through peer groups, identified any other ongoing trials. We examined any relevant retraction statements and errata for included studies. </p> </section> </section> <section id="CD013002-sec-0026"> <h3 class="title" id="CD013002-sec-0026">Data collection and analysis</h3> <section id="CD013002-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two teams of two review authors (JS, TN and CC, PA) independently screened titles and abstracts of all potential studies we identified as a result of the search for inclusion and code them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. If there were any disagreements, a fifth review author arbitrated (KB). We retrieved the full‐text study reports/publications and two review authors (TN, JS) independently screened the full‐text and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreements through discussion or, if required, we consulted a third review author (KB). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD013002-bbs2-0060" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100.">Liberati 2009</a>). </p> </section> <section id="CD013002-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We use Covidence (<a href="http://www.covidence.org/home" target="_blank">www.covidence.org</a>), and extracted study characteristics and outcome data onto a form piloted on at least one study in the review. We included studies irrespective of whether measured outcome data were reported in a usable way. </p> <p>Two review authors (CC and JS) extracted the following study characteristics.</p> <p> <ol id="CD013002-list-0005"> <li> <p>Methods: study design, total duration of study, number of study centres and location, study setting, withdrawals, date of study. </p> </li> <li> <p>Participants: number of participants randomised to the intervention, number of participants lost to follow‐up, number of participants analysed, mean age, age range, gender, cause of cardiogenic shock, diagnostic criteria, baseline lung function, smoking history, lactate prior to initiating MCS. </p> </li> <li> <p>Interventions: type of MADs, duration from diagnosis to intervention, duration of treatment, comparison, concomitant medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported, number lost to follow‐up, reasons for loss to follow‐up. </p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (CC and JS) independently extracted outcome data from included studies. We resolved disagreements by consensus or by involving a third review author (PA). One review author (TN) transferred data into Review Manager 5 (<a href="./references#CD013002-bbs2-0066" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the review with the study reports. A second review author (JS) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD013002-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TNH and JS) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013002-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another review author (PA). We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD013002-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We assessed selective outcome reporting bias by comparing the outcomes reported with the outcomes planned based on clinical trial registries/published protocols. </p> <p>We graded each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013002-sec-0030"> <h5 class="title">Assessment of bias in conducting the review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD013002-sec-0087">Differences between protocol and review</a> section of the review (<a href="./references#CD013002-bbs2-0079" title="Ni hlciT , BoardmanHM , BaigK , AifesehiPE , StaffordJL , CerneiC , et al. Mechanical assist devices for acute cardiogenic shock. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD013002]">Ni hlci 2018</a>). </p> </section> </section> <section id="CD013002-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>It was our intention to conduct the meta‐analysis using the most informative outcome and matching methods. Given that our primary outcome was patient survival this would (ideally) involve the use of individual participant data (IPD) and the tools of survival analysis. Therefore, we contacted the authors of studies identified in the review to request this data. If such data were available for a sufficient number of studies, we would have performed the meta‐analysis using Cox Regression with mixed effects, following the recommendations of a review of methods (<a href="./references#CD013002-bbs2-0034" title="AustinPC . A tutorial on multilevel survival analysis: methods, models and applications. International Statistical Review2017;85(2):185-203.">Austin 2017</a>). We would then have conducted analysis using Poisson Regression modes and reported hazard ratios (HRs) (<a href="./references#CD013002-bbs2-0073" title="SimmondsMC , HigginsJP , StewartLA , TierneyJF , ClarkeMI , ThompsonSG . Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials2005;2:209-17.">Simmonds 2005</a>). However, we were unable to obtain IPD in all cases, and it was necessary to resort to using aggregated data. In the case that we were required to use aggregate data, we opted for binary survival at 30 days. </p> <p>In addition to the primary measures, we collected and reported on outcomes such as overall survival, survival to transplant, survival to unsupported cardiac function and major adverse events where possible. We reported confidence intervals (CI) of time to death and time to major adverse events, along with point estimates. We planned to describe dichotomous data relating to status at a fixed time point using risk ratios (RRs) with corresponding CI (<a href="./references#CD013002-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). For continuous outcomes, we calculated the mean difference (MD) between the treatment arms at the end of follow‐up, if all trials measured the outcome on the same scale, otherwise we pooled standardised mean differences (SMDs), with 95% CI. </p> </section> <section id="CD013002-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>Where studies reported multiple observations for the same participant, we included the data according to the closest time point where applicable (e.g. survival at 30 days and survival at one year). For quality of life data, we planned to include the last follow‐up point collected and, for adverse event data, we included the first event in meta‐analyses and described additional events for the same individual in the text. </p> <p>In multiple‐arm studies, where more than two interventional arms met the eligibility criteria, we planned to combine the two device arms to have a single comparator (best current intensive care management, including IABP and inotropic support). </p> <p>As the intervention was in the setting of a life‐threatening event, cross‐over trials would not be possible, thus we did not anticipate finding cross‐over trials. </p> <p>To avoid unit of analysis errors in cluster‐RCTs, we conducted the analysis at the same level as the allocation, using a summary measurement from each cluster. Then the sample size is the number of clusters and analysis proceeds as if the trial was individually randomised (though the clusters become the individuals). However, this might considerably, and unnecessarily, reduce the power of the study, depending on the number and size of the clusters; we planned to acknowledge this as a limitation. </p> </section> <section id="CD013002-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD013002-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity qualitatively by comparing the clinical and methodological characteristics of the included trials and by visual inspection of forest plots to assess the degree of overlap in the CIs. </p> <p>We compared heterogeneity quantitatively using the Chi² test of heterogeneity and the I² statistic in each analysis. We considered a Chi² test resulting in P less than 0.1 indicating significant statistical heterogeneity. We interpreted I² statistics in the following manner: 0% to 40%, potentially not important; 30% to 60%, moderate heterogeneity; 50% to 90%, substantial heterogeneity and 75% to 100%, considerable heterogeneity (<a href="./references#CD013002-bbs2-0042" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). </p> <p>If we found very high heterogeneity, we first checked the data specifically, questioning any outliers. If the data were correct, we would have explored the results to understand why there was heterogeneity, and identify the factors that may be causing the variation between studies. If we found any modifiers, we would have cautiously reported the overall and subgroup analysis. We noted that the subgroup analysis was rarely randomised and we cautioned that our results should be considered observational and hypothesis‐generating, rather than definitive. </p> <p>If we had identified substantial or considerable heterogeneity, we would had report it and explored possible causes using prespecified subgroup analysis. </p> <p>If the studies were too dissimilar in clinical (population, setting, intervention) and methodological heterogeneity (study design, risk of bias) and there was a high level of heterogeneity on visual inspection of the forest plots (I² greater than 90% and Chi² with P less than 0.1), then we planned not to proceed with meta‐analysis (<a href="./references#CD013002-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD013002-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to pool more than 10 trials, we planned to create and analyse a funnel plot to explore possible reporting biases for the primary outcomes. </p> </section> <section id="CD013002-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only where this was meaningful, that is, if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. </p> <p>We would have used a random‐effects model for pooling of treatment effects, since the studies would differ in the mixes of participants and in the implementations of MADs (<a href="./references#CD013002-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p>We would have presented all results with the corresponding 95% CIs. We would have conducted all analyses according to the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013002-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and with the statistical components of Review Manager 5 software (<a href="./references#CD013002-bbs2-0066" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>If sufficient, clinically similar studies had been available, we would have pooled the results in meta‐analyses. For time‐to‐event data, we would have pooled HRs using the generic inverse variance facility of Review Manager 5 (<a href="./references#CD013002-bbs2-0066" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). For dichotomous outcomes, we would have calculated the RR for each study and then pooled them. For continuous outcomes, we would have pooled the MDs between the treatment arms at the end of follow‐up if all trials measure the outcome on the same scale, otherwise we would have pooled the SMDs. </p> <p>We would have descriptively summarised the studies for which pooling of results was not possible. </p> </section> <section id="CD013002-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD013002-list-0007"> <li> <p>Neonatal (less than 28 days of age)/paediatric (28 days to 16 years of age)/adult (greater than 16 years of age). </p> </li> <li> <p>Cause of ACS/ischaemic heart disease/cardiomyopathy/acute myopericarditis.</p> </li> <li> <p>MAD compared with IABP.</p> </li> <li> <p>MAD compared with best medical therapy excluding IABP.</p> </li> <li> <p>Percutaneous MADs (pMAD) (using Seldinger insertion technique) versus surgical MADs (inserted via sternotomy/thoracotomy). </p> </li> <li> <p>Long‐term MCS devices (durable LVAD) compared with short‐term MCS devices (for example, ECMO, Impella). </p> </li> <li> <p>Participants who had refractory cardiac arrest compared with participants with no cardiac arrest at the time of device implantation. </p> </li> </ol> </p> <p>We used the following outcomes in subgroup analyses.</p> <p> <ol id="CD013002-list-0008"> <li> <p>Survival (to discharge/30 days/1 year/to end of follow‐up).</p> </li> <li> <p>Major adverse events (to discharge/30 days/1 year/to end of follow‐up).</p> </li> </ol> </p> <p>We used the formal test for subgroup interactions in Review Manager 5 (<a href="./references#CD013002-bbs2-0066" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD013002-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analysis.</p> <p> <ol id="CD013002-list-0009"> <li> <p>Only including studies with a low risk of bias across all domains.</p> </li> </ol> </p> <section id="CD013002-sec-0039"> <h5 class="title">Brief economic commentary</h5> <p>We developed a brief economic commentary based on current methods guidelines to summarise the availability and principal findings of trial‐based and model‐based economic evaluations (cost‐analyses, cost‐effectiveness analyses, cost‐utility analyses and cost‐benefit analyses) (<a href="./references#CD013002-bbs2-0071" title="ShemiltI , MugfordM , ByfordS , DrummondM , EisensteinE , KnappM , et al. Chapter 15: Incorporating economics evidence In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Shemilt 2011</a>; <a href="./references#CD013002-bbs2-0072" title="ShemiltI , MugfordM , ValeL , CraigD , Campbell and Cochrane Economics Methods Group. Searching NHS EED and HEED to inform development of economic commentary for Cochrane intervention reviews. www.methods.cochrane.org/economics/workshops (accessed 13 July 2017).">Shemilt 2017</a>), that compare the use of MADs to best current intensive care management, including IABP and inotropic support. We identified relevant studies for this brief economic commentary during searches conducted for the review and during supplementary searches performed in accordance with search strategies developed by the Cochrane Economics Methods Group (<a href="./references#CD013002-bbs2-0072" title="ShemiltI , MugfordM , ValeL , CraigD , Campbell and Cochrane Economics Methods Group. Searching NHS EED and HEED to inform development of economic commentary for Cochrane intervention reviews. www.methods.cochrane.org/economics/workshops (accessed 13 July 2017).">Shemilt 2017</a>). This commentary focused on the extent to which principal findings of eligible economic evaluations indicated that an intervention might be judged favourably (or unfavourably) from an economic perspective, when implemented in different settings. </p> </section> <section id="CD013002-sec-0040"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice and our implications for research would suggest priorities for future research and outline any remaining uncertainties in the area. </p> </section> </section> <section id="CD013002-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a 'Summary of findings' table with the following outcomes and two time points. </p> <section id="CD013002-sec-0042"> <h5 class="title">Primary</h5> <p> <ol id="CD013002-list-0010"> <li> <p>Survival (30 days/end of follow‐up).</p> </li> <li> <p>Survival (to transplant or unsupported cardiac function/end of follow‐up).</p> </li> </ol> </p> </section> <section id="CD013002-sec-0043"> <h5 class="title">Secondary</h5> <p> <ol id="CD013002-list-0011"> <li> <p>Quality of life (using a validated quality of life scale or questionnaire; 30 days/end of follow‐up). </p> </li> <li> <p>Major adverse cardiovascular events (30 days/end of follow‐up).</p> </li> <li> <p>Dialysis‐dependent (30 days/end of follow‐up).</p> </li> <li> <p>Length of hospital stay and length of intensive care unit stay.</p> </li> <li> <p>Major adverse events, for example, deep sternal wound infection, prolonged ventilation (30 days/end of follow‐up). </p> </li> </ol> </p> <p>The comparison described in the 'Summary of findings' table would be MADs compared to best current intensive care management, including IABP and inotropic support. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013002-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), using GRADEpro GDT software (<a href="./references#CD013002-bbs2-0048" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.Available at gradepro.org.">GRADEpro GDT</a>). Two review authors (CC and JS) independently assessed the quality of the evidence and decided on downgrading and upgrading. If no agreement could be reached, a third review author (PA) resolved the disagreement. We justified all decisions to downgrade or upgrade the quality of the evidence using footnotes and we provided comments to aid the reader's understanding of the review where necessary. We planned to create one overall 'Summary of findings' table for our main analysis of MADs compared to best current intensive care management (inotropic support and IABP). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013002-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013002-sec-0044"></div> <section id="CD013002-sec-0045"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD013002-sec-0089" title="">Characteristics of included studies</a>; <a href="./references#CD013002-sec-0090" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD013002-sec-0046"> <h4 class="title">Results of the search</h4> <p>The searches resulted in 5616 citations and an additional 11 references were identified from the papers' reference lists and review of the ongoing clinical trials. We removed 1101 duplicates, resulting in 4515 citations for screening. See <a href="#CD013002-fig-0001">Figure 1</a> for full details of the process. </p> <div class="figure" id="CD013002-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. RCT: randomised controlled trial." data-id="CD013002-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. RCT: randomised controlled trial.</p> </div> </div> </div> <p>We excluded 4473 records on the basis of information in the title and abstract. We retrieved the full text of 42 references, which were screened independently by two review authors (TNH and CC). Thirty of these did not meet the inclusion criteria. </p> <p>Twelve references of five RCTs met the inclusion criteria, and were included in the review. One trial had four publications (<a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>), two trials had three publications (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>), one trial had one paper (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>), and one trial was described in a conference abstract only (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>). </p> <p>The search for conference proceedings, meeting abstracts and ongoing trials in databases such as ClinicialTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) yielded four ongoing trials relevant to this review (<a href="./references#CD013002-bbs2-0028" title="NCT01633502. Danish cardiogenic shock trial (DanShock). clinicaltrials.gov/ct2/show/NCT01633502 (first received 4 July 2012). ">DanGer Shock Trial</a>; <a href="./references#CD013002-bbs2-0029" title="NCT02544594. Clinical study of extra-corporal life support in cardiogenic shock complicating acute myocardial infarction. clinicaltrials.gov/show/NCT02544594 (first received 9 September 2015). NCT03637205. Extracorporeal life support in cardiogenic shock (ECLS-SHOCK). clinicaltrials.gov/ct2/show/NCT03637205 (first received 17 August 2018). ">ECLS‐SHOCK</a>; <a href="./references#CD013002-bbs2-0030" title="NCT02301819. Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS). clinicaltrials.gov/ct2/show/NCT02301819 (first received 26 November 2014). ">ECMO‐CS</a>; <a href="./references#CD013002-bbs2-0031" title="NCT03813134. Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in cardiogenic shock. clinicaltrials.gov/show/NCT03813134 (first received 23 January 2019). ">EuroShock</a>). </p> </section> <section id="CD013002-sec-0047"> <h4 class="title">Included studies</h4> <p>Five prospective RCTs randomised people with ACS to a MAD or best medical management including the use of an IABP. Two studies included all causes of ACS (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>), and three studies included people with ACS only caused by acute myocardial infarction (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>; <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>). The two studies that included all causes of ACS randomised participants to the TandemHeart percutaneous VAD while those that included people with ACS due to acute myocardial infarction were randomised to the percutaneous Impella CP (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). </p> <p>The total number of participants included in the five studies was 162 (13 to 41 participants included in each study). Four studies described the gender of the 148 participants, 75% of who were male (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). The number of centres ranged from one (<a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>) to 12 (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>). The mean age of participants receiving MAD ranged from 58 to 65.7 years and those in the control group from 58 to 67 years. Three studies described the mean lactate concentration prior to initiating treatment (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>); in the MAD group this ranged from 4.1 mg/dL (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>) to 7.5 mg/dL (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>), and in the IABP group from 3.8 mg/dL (<a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>) to 8.9 mg/dL (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). </p> <p>Of note, there were no studies investigating people after cardiotomy shock, and there were no studies that included people under the age of 18 years. In the people who presented with acute myocardial infarction, coronary revascularisation was performed prior to initiation of mechanical support in 69% of cases (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). Two studies described the time from diagnosis to initiation of support, which ranged from 4.5 hours to 11 hours and was similar in the MAD and IABP groups (<a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). Three studies described the duration of treatment (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>); the mean ranged from 23 hours to four days, with those in <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a> having the shortest duration of support and <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> the longest. </p> </section> <section id="CD013002-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded 22 studies. Of these, 11 investigated an ineligible cohort whereby MADs were used in people with chronic heart failure, or in cohorts of high‐risk percutaneous interventions (<a href="./references#CD013002-sec-0090" title="">Characteristics of excluded studies</a> table). </p> <section id="CD013002-sec-0049"> <h5 class="title">Ongoing studies</h5> <p>We found four ongoing studies (<a href="./references#CD013002-bbs2-0028" title="NCT01633502. Danish cardiogenic shock trial (DanShock). clinicaltrials.gov/ct2/show/NCT01633502 (first received 4 July 2012). ">DanGer Shock Trial</a>; <a href="./references#CD013002-bbs2-0029" title="NCT02544594. Clinical study of extra-corporal life support in cardiogenic shock complicating acute myocardial infarction. clinicaltrials.gov/show/NCT02544594 (first received 9 September 2015). NCT03637205. Extracorporeal life support in cardiogenic shock (ECLS-SHOCK). clinicaltrials.gov/ct2/show/NCT03637205 (first received 17 August 2018). ">ECLS‐SHOCK</a>; <a href="./references#CD013002-bbs2-0030" title="NCT02301819. Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS). clinicaltrials.gov/ct2/show/NCT02301819 (first received 26 November 2014). ">ECMO‐CS</a>; <a href="./references#CD013002-bbs2-0031" title="NCT03813134. Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in cardiogenic shock. clinicaltrials.gov/show/NCT03813134 (first received 23 January 2019). ">EuroShock</a>; <a href="./references#CD013002-sec-0091" title="">Characteristics of ongoing studies</a> table). </p> </section> </section> </section> <section id="CD013002-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of each study is summarised in <a href="#CD013002-fig-0002">Figure 2</a> with details for each judgement provided in the <a href="./references#CD013002-sec-0089" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD013002-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013002-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013002-sec-0051"> <h4 class="title">Allocation</h4> <section id="CD013002-sec-0052"> <h5 class="title">Random sequence generation</h5> <p>Random sequence generation was unclear in three studies as there was no clear method described to how the randomisation processes was performed (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>; <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>). Two studies were clear regarding the timing of randomisation and method of doing so and were therefore at low risk of bias in this domain (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). </p> </section> <section id="CD013002-sec-0053"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was unclear in three studies (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>; <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>). <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a> was a prospective two centre RCT that, after initial assessment of haemodynamics, randomly assigned eligible participants to either treatment with IABP or Impella LP2.5, but further details of the randomisation were not clarified. In <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>, there was a roll‐in phase of nine participants into the study prior to initiation of the randomisation of the subsequent 33 participants, the method of randomisation was not described. <a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a> did not describe any methods. </p> <p>Allocation concealment was at low risk of bias in the remaining two studies (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> performed randomisation by drawing sealed envelopes and <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> performed it in a 1:1 ratio using an Internet‐based application. </p> </section> </section> <section id="CD013002-sec-0054"> <h4 class="title">Blinding</h4> <p>Performance bias unclear in all the studies. None of the studies described any methods of blinding of participants or personnel. </p> <p>Detection bias was low in one study where the outcome assessment was clearly blinded as an independent clinical event committee adjudicated the events (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). Imaging parameters were assessed by independent local core laboratories that were blinded to the other trial data and randomisation outcome (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). The other four studies did not describe any attempts at blinding the outcome assessors, thus were deemed to have unclear risk for detection bias (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>; <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). </p> </section> <section id="CD013002-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition bias was low in four studies as they described complete outcome data for the 30‐day survival outcome. One participant was lost to follow‐up when assessing the six‐month outcome (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). One study was at high risk for attrition as two randomised participants were not included or accounted for in the analysis (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>). </p> </section> <section id="CD013002-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Selective reporting bias was low as all that was described in the methods of all five studies were reported and the data were complete in all studies. </p> </section> <section id="CD013002-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>There were no other identified biases in the included studies. </p> </section> </section> <section id="CD013002-sec-0058"> <h3 class="title" id="CD013002-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD013002-tbl-0001"><b>Summary of findings 1</b> Mechanical assist devices compared to intra‐aortic balloon pump for acute cardiogenic shock at 30‐day follow‐up</a> </p> <p>Meta‐analysis was performed only to assess the 30‐day survival as there was insufficient data to perform any further meta‐analysis. </p> <section id="CD013002-sec-0059"> <h4 class="title">Survival (30 day)</h4> <p>The results from the five studies with 162 participants showed that there was little or no effect in 30‐day survival, with an RR of 1.01 (95% CI 0.76 to 1.35). The GRADE of the evidence was classed as very low which means we are uncertain about the finding. </p> <p>One of the five trials was powered to assess an absolute reduction in the 30‐day survival (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>), the others had 30‐day survival as secondary outcomes. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> reported that there was no significant difference in 30‐day survival in the pMAD group (54%) versus the IABP group (50%), with an HR of 0.96 (95% CI 0.42 to 2.18). </p> <p>Overall, of the 162 participants included, 84 had MAD, 40 of whom survived to 30 days (47.6% survival) and 78 had IABP, of whom 39 survived (50% survival). </p> <p>No study described whether participants went on to have a transplant or unsupported cardiac care. </p> <p>Subgroup analysis assessing the type of MAD comparing those who received TandemHeart (two studies; <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>) to those who received other devices (<a href="./references#CD013002-bbs2-0001" title="Bonnefoy-CudrazE , HuotL , ElbazM , CottinY , RouxA , BouchotO , et al. Mechanical circulatory support with the Impella 5.0 and intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction. The IMPELLA-STIC study. European Heart Journal2014;1:1063. ">Bonnefoy‐Cudraz 2014</a>: Impella LP 5.0 plus IABP; <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>: Impella CP plus IABP: <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>: Impella CP) demonstrated no statistical difference between the two groups' survival outcomes at 30 days (Chi² = 0.20, df = 1 (P = 0.66); I² = 0%). </p> </section> <section id="CD013002-sec-0060"> <h4 class="title">Survival (to transplant or unsupported cardiac function/end of follow‐up)</h4> <p>None of the studies gave details regarding survival beyond 30 days and there were no data regarding the number of participants who survived to transplant or unsupported cardiac function. </p> </section> <section id="CD013002-sec-0061"> <h4 class="title">Quality of life</h4> <p>None of the studies assessed quality of life in people who underwent treatment for ACS with IABP or MAD. </p> </section> <section id="CD013002-sec-0062"> <h4 class="title">Major adverse cardiovascular events</h4> <p>Three studies described major adverse cardiovascular events in a heterogeneous manner (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). There were no clear definitions for major adverse cardiovascular events in any of the published studies. Cerebrovascular accident was described to have occurred in one participant who had a MAD and one participant who had IABP only; these were both in <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> and both CVA were ischaemic. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> was the only study to describe if any cases had myocardial reinfarction reporting that this occurred in one participant who had MAD and two participants who had IABP only. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> described that one participant had a major vascular complication, with a retroperitoneal bleed after pMAD insertion. Limb ischaemia occurred in three of the MAD group and none in the IABP group. <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> described that seven participants developed limb ischaemia following insertion of a 17‐French arterial cannula. Limb ischaemia could be resolved by surgical approach in three participants and by percutaneous approach in four participants. <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a> described one case of limb ischaemia requiring surgery after device explantation in a participant assigned to Impella MAD. </p> </section> <section id="CD013002-sec-0063"> <h4 class="title">Dialysis‐dependent</h4> <p>Only one study described if any cases required renal replacement therapy following the episode of ACS (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). They described that 33% of the MAD group and 29% of the IABP group required renal replacement therapy. </p> </section> <section id="CD013002-sec-0064"> <h4 class="title">Length of hospital stay</h4> <p>One study described the length of hospital stay after initiation of treatment (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). The mean length of stay in the MAD group was 16 days (range 3 days to 26 days) and in the IABP alone group 10 days (range 6 days to 24 days). </p> </section> <section id="CD013002-sec-0065"> <h4 class="title">Length of intensive care unit stay</h4> <p><a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> was the only study to report length of intensive care unit stay. The mean length of stay in the MAD group was 7 days (range 3 to 16 days), and in the IABP alone group was 7 days (range 4 to 10 days). </p> </section> <section id="CD013002-sec-0066"> <h4 class="title">Major adverse events</h4> <p>Three studies described major adverse events (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a> described one incident of TandemHeart failure and one event where the device had to be removed because of a device‐related problem (blood clotting in the cannula; activated clotting time documented to be 182 seconds, which is less than the recommended 200 seconds to 250 seconds). They described that systemic infection or sepsis occurred in four (21.1%) of the MAD group and five (35.7%) of the IABP group. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> described major bleeding occurred in eight (33%) of the MAD group and two (8%) of the IABP group. They postulated the reason for this was those with mechanical support received heparin in addition to standard dual antiplatelet therapy after percutaneous coronary intervention (PCI). <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> described that 13 (61%) participants in the VAD group and three (15%) participants in the IABP group had signs of disseminated intravascular coagulation (DIC). In the three participants with IABP, DIC was mild and could be resolved by substitution with antithrombin III. In eight participants with VAD, DIC was severe with subsequent haemorrhagic diathesis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013002-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013002-sec-0067"></div> <section id="CD013002-sec-0068"> <h3 class="title" id="CD013002-sec-0068">Summary of main results</h3> <p>This systematic review identified five prospective RCTs studying adults with ACS who were randomised to treatment with MADs or current best medical practice including the use of an IABP. Two studies included all causes of ACS and the MAD used was TandemHeart and two studies included only cases of cardiogenic shock secondary to acute myocardial infarction and the MAD used was Impella. </p> <p>None of the studies were powered to assess if MADs improve survival in people with ACS, thus the primary objective of this review was unachievable. Four studies described 30‐day outcomes and there was little or no effect in the 30‐day survival. No RCT assessed survival to transplant or unsupported cardiac function beyond six months. </p> <p>Major adverse cardiovascular rates and major adverse event rates are not described consistently across the four trials and we are unable to conclude whether MAD led to an increased rate of complications. Three trials described limb ischaemia and found a trend towards an increase rate of limb ischaemia with MAD. This may be an issue with the catheter size as 33% of the participants in <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> who had MAD with TandemHeart and a 17‐French catheter had issues with peripheral limb ischaemia. </p> <p>Based on the current published RCTs, we were unable to assess and formulate a brief economic commentary, and subgroup analysis was only possible for one outcome. </p> </section> <section id="CD013002-sec-0069"> <h3 class="title" id="CD013002-sec-0069">Overall completeness and applicability of evidence</h3> <p>There are several limitations to the evidence base reviewed. Both the number of trials that met the inclusion criteria for the review and also the number of participants included in the review were low. Not all the prespecified outcomes for the review were included in all the trials and some were not reported by any included trial. The condition studied, with its acute nature, rapid deterioration and high mortality make RCTs challenging to undertake. </p> <p>There are several different devices for MCS, two different forms were included in this review; two trials (74 participants) utilised the TandemHeart and recruited between 2002 and 2004 and 2000 and 2003; two trials (74 participants) utilised the Impella device and recruited between 2012 and 2015 and 2004 and 2007. Further devices have been developed and are being developed and it is likely that there may be differences in the effects between devices. The small number of participants included did not permit subgroup analysis to compare effect sizes according to device type. With the available evidence, we were unable to determine if MCS did offload pharmacological support or not.  </p> <p>Research is often undertaken at larger academic medical institutions which often carry out higher volumes of procedures, it is established that health outcomes are improved in high‐volume centres and it may be that outcomes would not be so good and adverse event rates higher in those undergoing MCS in smaller cardiac surgical centres. </p> </section> <section id="CD013002-sec-0070"> <h3 class="title" id="CD013002-sec-0070">Quality of the evidence</h3> <p>A summary of the findings and strength of evidence for comparing MCS and IABP can be found in <a href="./full#CD013002-tbl-0001">summary of findings Table 1</a>. </p> <p>The evidence for 30‐day survival was downgraded to very‐low certainty, due to study limitations (risk of bias in key domains) and very serious concerns about imprecision that related to the very small sample size and wide CIs including both the possibility of benefit and harm. Future evidence is highly likely to change the estimated effect. </p> <p>The quality of evidence for the secondary outcomes was downgraded to very‐low certainty. No studies described quality of life outcomes. Three studies described major adverse cardiovascular events 30‐day follow‐up (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>), and three studies reported major adverse events at 30‐day follow‐up (<a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a>; <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>); reporting was heterogeneous without any clear definitions in any of the studies. Dialysis‐dependence, length of hospital stay and length of intensive care unit stay were described in one trial each. </p> </section> <section id="CD013002-sec-0071"> <h3 class="title" id="CD013002-sec-0071">Potential biases in the review process</h3> <p>We all work to try to improve the outcomes in hopeless situations and we have an inherent bias to try to save lives. All trials under‐represented women in their study populations (75% of the participants in the studies were male). Due to the nature of the intervention the trials were not blinded; however, due to the main outcome being survival it is unlikely that a lack of blinding had an impact on this. Despite extensive searches, it is possible that we were not able to identify all relevant studies. </p> </section> <section id="CD013002-sec-0072"> <h3 class="title" id="CD013002-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>The findings of this review are consistent with other reviews published in this field. The European Society of Cardiology updated their guidance on the management of cardiogenic shock complicating myocardial infarction (<a href="./references#CD013002-bbs2-0044" title="ThieleH , OhmanEM , deWaha-ThieleS , ZeymerU , DeschS . Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal2019;40:2671-83.">ESC 2019</a>), they concluded that, despite an increasing number of pMAD data derived from clinical trials on the effectiveness safety, differential indications for different devices and optimal timing are limited. The authors of three of the RCTs described in this review, collaborated and published a review and collaborative meta‐analysis including individual patient data concluded that there was no difference in mortality for 148 included participants. They found that there was improvement in arterial lactate and mean arterial blood pressure after device insertion. Counterbalancing this, however, were significantly more bleeding complications in the MAD group (<a href="./references#CD013002-bbs2-0075" title="ThieleH , JobsA , OuweneelDM , HenriquesJP , SeyfarthM , DeschS , et al. Percutaneous short term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal2017;38:3523-31.">Thiele 2017</a>). </p> <p>The Uspella registry reported on 15,259 people with acute myocardial infarction cardiogenic shock treated with Impella (2.5, CP or 5.0) in 1010 US hospitals and, of the total patients, 51% survived to explantation (<a href="./references#CD013002-bbs2-0037" title="BasirMB , SchrieberTL , GrinesCL , DixonSR , MosesJW , ManiBS , et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. American Journal of Cardiology2017;119:845-51.">Basir 2016 USpella registry</a>). Of note, there were wide variations in survival observed on hospital sites, they found significant differences between survival at the time of explantation across various settings (30% survival rate among the lowest quintiles less than 1 Impella case/year versus 76% among the top quintile greater than 7 cases/year; P &lt; 0.001). They identified two variables associated with improved survival, the timing of the MAD and haemodynamic monitoring. Clinicians used MAD as first‐line treatment or as salvage after inotropic or balloon pump therapy failure. Data on MAD was available in 5571 people and they found that use of MCS devices as first‐line treatment was associated with a 59% survival rate as compared with 52% when used as a salvage strategy (P &lt; 0.001). When investigating the impact of invasive haemodynamic monitoring using pulmonary artery catheters on outcome in 13,984 people, they found that the survival rate among people who received haemodynamic monitoring was 63% compared with 49% in those who did not (P &lt; 0.001). They found that older age was associated with a lower survival (OR 0.98, 95% CI 0.97 to 0.99; P &lt; 0.0001). In people aged less than 50 years, 61.2% survived to explant versus 45.1% of people aged over 80 years of age) and that Impella used before PCI was independently associated with better survival (OR 1.34, 95% CI 1.2 to 1.5; P &lt; 0.001), and that Impella CP was also associated with better survival compared with Impella2.5 (OR 1.28, 95% CI 1.12 to 1.47; P = 0.003). </p> <p>International guidelines in ACS highlight the difficulty both ethically and practically in RCTs adequately powered to detect differences in clinical outcomes achieved as a result most of the trials have been underpowered and guideline recommendations are driven mostly by expert consensus (<a href="./references#CD013002-bbs2-0044" title="ThieleH , OhmanEM , deWaha-ThieleS , ZeymerU , DeschS . Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal2019;40:2671-83.">ESC 2019</a>). Currently, early revascularisation is the only proven treatment to reduce mortality in acute myocardial infarction complicated by cardiogenic shock (<a href="./references#CD013002-bbs2-0053" title="HochmanJS , SleeperLA , WebbJG , SanbornTA , WhiteHD , TalleyJD , et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine1999;341:625-34.">Hochman 1999</a>), but the extent of the revascularisation limited to the culprit lesion only (<a href="./references#CD013002-bbs2-0076" title="ThieleH , KinI , SandriM , FuernauG , deWahaS , Meyer-SaraeiR , et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. New England Journal of Medicine2017;377:2419-32.">Thiele 2017 CULPRIT Shock Trial</a>). But, despite the complexities and difficulties in performing clinical studies in cardiogenic shock, it now has been repeatedly shown that such trials can be successfully performed and international collaboration to build large cardiogenic shock research networks to answer the multiple open questions in the treatment of cardiogenic shock. </p> <p>Currently there are four ongoing randomised control trials investigating the role of MAD in cardiogenic shock, powered to show a mortality benefit for MAD (one Impella, three VA ECMO). <a href="./references#CD013002-bbs2-0041" title="UdesenNJ , MollerJE , LindholmMG , EiskjaerH , SchaferA , WernerN , et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. American Heart Journal2019;214:69-8.">DanGer Shock 2019</a> has published the trial design along with the characteristics of the first 100 participants randomised. This collaborative trial will be the first adequately powered trial to address whether MCS with Impella CP can improve survival in acute myocardial cardiogenic shock. This trial has clear protocols published. Issues regarding consent are clear as in Denmark written informed proxy consent from relatives is obtained and in Germany the principle investigators' inability to obtain informed consent due to the urgency of the situation should be backed up by an independent physician, and the principle investigator assesses and acts according to supposed patients will. All centres must have direct access to an Internet‐based randomisation system and if the patient is randomised to the treatment then Impella CP is placed before revascularisation. Patients with an out‐of‐hospital cardiac arrest with persistent Glasgow Coma Scale less than 8 after return of spontaneous circulation are excluded from this study and only patients with arterial lactate greater than 2.5 mmol/L. In the ICU, patients irrespective of randomisation group are recommended to have invasive cardiovascular monitoring including a pulmonary artery catheter. No weaning attempts are done in the initial 48 hours, if there is stability at 48 hours, weaning should be attempted. If weaning leads to haemodynamic instability the device should be maintained and daily weaning attempts performed. After one week of support, escalation should be considered to venoarterial ECMO or LVAD. Guidance on the management of complications from the device is also clearly stipulated. </p> <p>The published trials included in our review did not exclude people with out‐of‐hospital arrest. In the case of the largest trial, IMPRESS in Severe Shock trial, all their participants were mechanically ventilator prior to randomisation, and, overall, 92% of the included participants had an out‐of‐hospital cardiac arrest with a median duration of chest compression of more than 20 minutes and 25% of resuscitated participants were resuscitated for more than 45 minutes implying a significant risk of hypoxic cerebral injury (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>). They found that the primary cause of death at six months was brain damage in 46% and death due to refractory cardiogenic shock occurred in 29% of the deceased participants. It has been speculated that the inclusion of out‐of‐hospital cardiac arrests contributed to the neutral result of the trial. Thus, the DanGer Shock trial has excluded these patients (<a href="./references#CD013002-bbs2-0041" title="UdesenNJ , MollerJE , LindholmMG , EiskjaerH , SchaferA , WernerN , et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. American Heart Journal2019;214:69-8.">DanGer Shock 2019</a>). However, they include people who had a cardiac arrest in the catheterisation laboratory or after the arrival of emergency services. As we were unable to obtain individual patient data and the numbers were so small, we were unable to perform a sensitivity analysis for the cohort of patients without cardiac arrest in this systematic review and meta‐analysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013002-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/urn:x-wiley:14651858:media:CD013002:CD013002-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. RCT: randomised controlled trial." data-id="CD013002-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_t/tCD013002-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. RCT: randomised controlled trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013002-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/urn:x-wiley:14651858:media:CD013002:CD013002-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013002-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_t/tCD013002-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013002-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/urn:x-wiley:14651858:media:CD013002:CD013002-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mechanical circulatory support (MCS) versus intra‐aortic balloon pump (IABP), Outcome 1: 30‐day survival" data-id="CD013002-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_t/tCD013002-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Mechanical circulatory support (MCS) versus intra‐aortic balloon pump (IABP), Outcome 1: 30‐day survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/references#CD013002-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/media/CDSR/CD013002/image_n/nCD013002-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013002-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mechanical assist devices compared to intra‐aortic balloon pump for acute cardiogenic shock at 30‐day follow‐up</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MAD compared to IABP for acute cardiogenic shock 30‐day follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with acute cardiogenic shock<br/><b>Setting:</b> hospital or intensive care unit<br/><b>Intervention:</b> MAD<br/><b>Comparison:</b> IABP </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IABP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MAD</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>30‐day survival</b> </p> <p>Follow‐up of 30 days was complete in all 5 studies.</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.01</b><br/>(0.76 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000<br/>(395 to 715) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No study described quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MACE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies described MACE events in a very heterogeneous manner without any clear definitions in any of the studies (<a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a>; <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a>; <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a>). CVA occurred in 1 participant who had a MAD and 1 participant who had IABP only (both in <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> and both CVA were ischaemic). <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> was the only study to describe if any cases had myocardial reinfarction reporting that this occurred in 1 participant who had MAD and 2 participants who had IABP only. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> described that 1 participant had a major vascular complication, with a retroperitoneal bleed after percutaneous MAD insertion. <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> described that 7 participants developed limb ischaemia following insertion of a 17‐French arterial cannula. Limb ischaemia could be resolved by surgical approach in 3 participants and by percutaneous approach in 4 participants. <a href="./references#CD013002-bbs2-0004" title="SeyfarthM , BauerI , SibbingD , Bott-FlugelL , KastratiA , SchomigA . A prospective and randomized trial to compare a left ventricular assist device (Impella LP2.5) with IABP in patients with cardiogenic shock by acute myocardial infarction: the ISAR-SHOCK trial. Circulation2007;116(16):929. SeyfarthM , SibbingD , BauerI , FrohlichG , Bott-FlugelL , ByrneR , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. Journal of the American College of Cardiology2008;52(19):1584-8. [DOI: dx.doi.org/10.1016/j.jacc.2008.05.065]SeyfarthM , SibbingD , GloeckT , Bott-FluegelL , BauerI , KastratiA , et al. Two-year outcome with the LVAD Impella LP2.5 compared to IABP for patients with cardiogenic shock by myocardial infarction: long term follow-up of a randomized trial (ISAR-SHOCK). European Heart Journal2009;1:157-8. ">Seyfarth 2008</a> described limb ischaemia requiring surgery after device explantation in 1 participant assigned to Impella MAD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dialysis‐dependent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8/24 33%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7/24 29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> reported 8/24 (33%) participants in MAD group and 7/24 (29%) in IABP group required dialysis with duration of treatment (median) 17 (25th to 75th percentile 5–29) days in MAD group and (median) 7 (25th to 75th percentile 2–9) days in IABP group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay (hospital)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study described length of stay <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> MAD median 16 days (25th to 75th percentile 2–26) and IABP median 10 days (25th to 75th percentile 6–24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of stay (ICU)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study described length of ICU stay <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> MAD median 7 days (25th to 75th percentile 3–16) IABP median 7 days (25th to 75th percentile 4–10) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b> </p> <p>Mean follow‐up time 30 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were heterogeneous. <a href="./references#CD013002-bbs2-0002" title="BurkhoffD , CohenH , BrunckhorstC , O'NeillWW , TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. American Heart Journal2006;152(3):469.e1-8. ">Burkhoff 2006</a> had 1 device failure TandemHeart blood clot in the cannula, also described 21.5% of participants in MAD group developed sepsis vs 35.7% in IABP group. <a href="./references#CD013002-bbs2-0003" title="NTR3450. IMPRESS in severe shock. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR3450 (first received 24 May 2012). OuweneelDM , EngstromAE , SjauwKD , HirschA , HillJM , GockelB , et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. International Journal of Cardiology2016;202:894-6. OuweneelDM , EriksenE , SjauwKD , vanDongenIM , HirschA , PackerEJ , et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2017;69(3):278-87. [DOI: dx.doi.org/10.1016/j.jacc.2016.10.022]">Ouweneel 2017</a> stated that 33% in MAD group had significant bleeding vs 8% in IABP. <a href="./references#CD013002-bbs2-0005" title="ThieleH , BoudriotE , SickP , NiebauerJ , DiederichKW , HambrechtR , et al. Randomized comparison of intra-aortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. Journal of the American College of Cardiology2004;43(5):234A. ThieleH , BoudriotE , SickR , DiederichKW , NiebauerJ , HambrechtR , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2004;25:73. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2005;26(13):1276-83. ThieleH , SickP , BoudriotE , DiederichKW , HambrechtR , NiebauerJ , et al. Randomized comparison of intraaortic balloon support versus a percutaneous left-ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal2003;24:25. ">Thiele 2005</a> stated that 61% in MAD group had evidence of DIC vs 15% in IABP group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CVA:</b> cardiovascular accident; <b>DIC:</b> disseminated intravascular coagulation; <b>IABP:</b> intra‐aortic balloon pump; <b>ICU:</b> intensive care unit; <b>MACE:</b> major adverse cardiovascular events; <b>MAD:</b> mechanical assist device; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: the majority of studies were at high or unclear risk of bias for at least one key domain.<br/><sup>b</sup>Downgraded two levels for imprecision: 95% CI is wide and includes the possibility of both harm and benefit, and the sample size is very low small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mechanical assist devices compared to intra‐aortic balloon pump for acute cardiogenic shock at 30‐day follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/full#CD013002-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013002-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mechanical circulatory support (MCS) versus intra‐aortic balloon pump (IABP)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 30‐day survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.76, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 TandemHeart device</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.64, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Other device</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.71, 1.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mechanical circulatory support (MCS) versus intra‐aortic balloon pump (IABP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013002.pub2/references#CD013002-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013002.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013002-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013002-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013002-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013002-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013002-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013002-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013002-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013002-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013002\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013002\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013002\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013002\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013002\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013002.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013002.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013002.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013002.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013002.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720203643"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013002.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720203646"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013002.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfb726a9f9377',t:'MTc0MDcyMDIwNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 